The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
REGULATORY
Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) is finally joining the NHI price list on November 22 after skipping two rounds of listing since it scored regulatory approval in March this year as Japan’s first obesity drug in three decades.…
To read the full story
Related Article
- As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
- Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
November 29, 2023
- Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
- Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
November 16, 2023
- Novo’s Obesity Med Wegovy Skips Listing Again in August
August 24, 2023
- Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
- Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
- Novo Mum over Pass on Wegovy Listing in May
May 19, 2023
- Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
May 17, 2023
- Wegovy First Med to Meet Guidelines Criteria for Obesity Drug Development
March 30, 2023
- Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
- Japan Approves Wegovy, Omvoh, FluMist, Entyvio SC and More
March 28, 2023
REGULATORY
- Japan Won’t Ban Red No. 3 for Now but Asks Industry for Self-Inspections
March 27, 2025
- It’s Time to Review Conditional Approval System for Regenerative Medicines: MHLW Official
March 27, 2025
- PMDA Stepping Up Efforts to Woo Overseas Startups to Japan
March 27, 2025
- MHLW Presents Expected Roles of Clinical Research Hospitals towards Criteria Review
March 26, 2025
- Raise Deduction Cap for Self-Medication Tax Break: OTC Industry Chief
March 26, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…